Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases
| Autor: | Luc Kuykens, Papa Salif Sow, Maria Rebollo Polo, Kileken Ole-Moiyoi, Morgane Guex, Aya Yajima, Ulrich-Dietmar Madeja, Julie Jacobson, Takayuki Hida, Daniel Argaw, Lynn Leonard, Rachel Taylor, Eric A. Ottesen, Jonathan D. King, Mark Bradley, Johannes Waltz, Adrian Hopkins, Julie Jensen, Jamsheed Mohamed |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Economic growth
medicine.medical_specialty pharmaceutical companies 030231 tropical medicine Context (language use) Review Article Global Health Onchocerciasis 03 medical and health sciences 0302 clinical medicine Tropical Medicine Global health medicine Humans Schistosomiasis AcademicSubjects/MED00860 030212 general & internal medicine neglected tropical diseases Pharmaceutical industry 2030 NTD roadmap business.industry Public health Public Health Environmental and Occupational Health Tropical disease Neglected Diseases General Medicine medicine.disease Infectious Diseases AcademicSubjects/MED00290 endemic countries Donation partnerships Neglected tropical diseases Parasitology business International development Corrigendum medicine donations |
| Zdroj: | Transactions of the Royal Society of Tropical Medicine and Hygiene |
| ISSN: | 1878-3503 |
| Popis: | Neglected tropical diseases (NTDs) are targeted for global control or elimination. Recognising that the populations most in need of medicines to target NTDs are those least able to support and sustain them financially, the pharmaceutical industry created mechanisms for donating medicines and expertise to affected countries through partnerships with the WHO, development agencies, non-governmental organisations and philanthropic donors. In the last 30 y, companies have established programmes to donate 17 different medicines to overcome the burden of NTDs. Billions of tablets, capsules, intravenous and oral solutions have been donated, along with the manufacturing, supply chains and research necessary to support these efforts. Industry engagement has stimulated other donors to support NTDs with funds and oversight so that the ‘heath benefit’ return on investment in these programmes is truly a ‘best value in public health’. Many current donations are ‘open-ended’, promising support as long as necessary to achieve defined health targets. Extraordinary global health advances have been made in filariasis, onchocerciasis, trachoma, trypanosomiasis, leishmaniasis, schistosomiasis, intestinal parasites and others; and these advances are taking place in the context of strengthening health systems and meeting the global development goals espoused by the WHO. The pharmaceutical manufacturers, already strong collaborators in initiating or supporting these disease-targeted programmes, have committed to continuing their partnership roles in striving to meet the targets of the WHO's new NTD roadmap to 2030. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|